Archives of Clinical Microbiology

  • ISSN: 1989-8436
  • Journal h-index: 24
  • Journal CiteScore: 8.01
  • Journal Impact Factor: 7.55
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • Open J Gate
  • Genamics JournalSeek
  • The Global Impact Factor (GIF)
  • Open Archive Initiative
  • China National Knowledge Infrastructure (CNKI)
  • Directory of Research Journal Indexing (DRJI)
  • OCLC- WorldCat
  • Proquest Summons
  • Publons
  • MIAR
  • University Grants Commission
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
  • Scimago Journal Ranking
  • Secret Search Engine Labs
  • ResearchGate
  • International Committee of Medical Journal Editors (ICMJE)
Share This Page


Extended spectrum �?²-lactamase in clinical isolates of Escherichia coli in a tertiary care centre

Kaiser Ahmed, Manzoor Thakur, Bashir Fomda Fomda, Gulnaz Bashir, Peer Maroof, SM Kadri

Background: The Extended Spectrum β-Lactamase (ESBL) producing organisms are increasing rapidly and becoming a major problem in the area of infectious disease. The present study was conducted to know the prevalence of ESBL producing Escherichia coli (E. coli ) isolated from different clinical specimens received in the Department of Microbiology at the Sheri-Kashmir institute of medical sciences, (SKIMS) and to observe the drugresistance pattern of these ESBL producing E. coli.

Methods: Various isolates of E. coli were obtained from patients admitted or attending Out Pateint Department (OPD) over a period of 2 years from 1st August 2005 to 31st July 2007. In this study, 221 E. coli were subjected to screening by using cefotaxime, ceftazidime and ceftriaxone 30mg discs.Among them, 211 were positive for potential ESBL production which were further subjected to confirmatory tests by the following Phenotypic methods;doubledisc synergy test (DDST), phenotypic confirmatory disc diffusion test (PCDDT) and E-test.

Findings: 55.9 % (118/211) of E.coli isolates were positive for ESBL production from different clinical specimen, highest number being from urine (72.9 %). The highest number of ESBL production were from inpatients (71.2 %) followed by outpatient (28.8 %).The resistance pattern of ESBL positive isolates showed higher resistance to 3rd and 4th generation cephalosporins (97.5 % to 99.2 %), quinolones (93.1 % to100 %) and aminoglycosides (65.2 %). They showed high degree of sensitivity to imipenem (98.3 %), nitrofurantoin (91.5 %), gatifloxacin (64.1 %) and amikacin (78.2 %).

Conclusions: The high prevalence of ESBL production among E. coli was observed which should alert the physician as it is associated with indiscriminate use of 3rd and 4th generation cephalosporins. The presence of ESBL in outpatient is of main concern as it can be responsible for communityacquired ESBL and can spread fast in our community. The multidrug resistance pattern of ESBL isolates was observed.